Phanes Therapeutics Announces FDA IND Clearance For PT217, an Anti-DLL/ Anti-CD47 Bispecific Antibody Being Developed For Patients With SMALL CELL LUNG CÁNCER ... También Obtuvo el Status de ORPHAN DRUG .